Adverse impact of high panel-reactive antibody (PRA) and positive cytotoxic crossmatch in liver transplantation.
Of 91 liver transplants (LTX) performed from October 1988 to December 1992, 13 (14.2%) of the patients received a liver from a lymphocytotoxic-positive crossmatch (CM) donor. Severe early rejection resulting in graft floss occurred in seven positive CM patients. Three of the remaining positive CM patients suffered several rejection episodes leading to chronic rejection and FK 506 was required as rescue treatment. A significant difference in mean panel-reactive antibody (PRA) of 8.6% and 56.9% was found in negative and positive CM patients, respectively (P = 0.012). A higher mean PRA (67.7%) was found in positive CM patients with rejection compared with positive CM patients without rejection (PRA 38%). Overall graft and patient survival were 31.9% and 35% in positive CM patients compared with 57.0% and 61.9% in negative CM patients. These differences were statistically significant (P = 0.023). In our experience the risk of developing severe acute rejection with graft failure and chronic rejection is related to PRA > 60% and positive CM. We recommend that in patients with PRA > 60%, the result of CM should be awaited before proceeding to LTX.
Charco
R
R
Liver Transplantation Unit, Hospital General Universitario de la Vall d'Hebron, Barcelona, Spain.
Balsells
J
J
Murio
E
E
Lázaro
J L
JL
Margarit
C
C
Martorell
J
J
D000328:Adult; D000906:Antibodies / Q000097:blood*; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D012189:Retrospective Studies
D000906:Antibodies; D006680:HLA Antigens